Anton Stalenhoef

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Koenen Tim B; Tack Cees J; Kroese Jeanne Margot; Hermus Ad R; Sweep Fred C G; van der Laak Jeroen; Stalenhoef Anton F H; de Graaf Jacqueline; van Tits Lambertus J H; Stienstra Rinke
Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.
Holewijn Suzanne; den Heijer Martin; Swinkels Dorine W; Stalenhoef Anton F H; de Graaf Jacqueline
The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis.
Hoogendam Arjen; de Vries Robbé Pieter F; Stalenhoef Anton F H; Overbeke A John P M
Evaluation of PubMed filters used for evidence-based searching: validation using relative recall.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Anton Stalenhoef (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Koenen Tim B; Tack Cees J; Kroese Jeanne Margot; Hermus Ad R; Sweep Fred C G; van der Laak Jeroen; Stalenhoef Anton F H; de Graaf Jacqueline; van Tits Lambertus J H; Stienstra Rinke
Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.
The Journal of clinical endocrinology and metabolism 2009;94(11):4453-7.
2009: Holewijn Suzanne; den Heijer Martin; Swinkels Dorine W; Stalenhoef Anton F H; de Graaf Jacqueline
The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis.
The Journal of clinical endocrinology and metabolism 2009;94(8):2893-9.
2009: Hoogendam Arjen; de Vries Robbé Pieter F; Stalenhoef Anton F H; Overbeke A John P M
Evaluation of PubMed filters used for evidence-based searching: validation using relative recall.
Journal of the Medical Library Association : JMLA 2009;97(3):186-93.
2009: Popa C; van Tits L J H; Barrera P; Lemmers H L M; van den Hoogen F H J; van Riel P L C M; Radstake T R D J; Netea M G; Roest M; Stalenhoef A F H
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Annals of the rheumatic diseases 2009;68(6):868-72.
2009: Henneman Peter; van der Sman-de Beer Femke; Moghaddam Payman Hanifi; Huijts Petra; Stalenhoef Anton F H; Kastelein John J P; van Duijn Cornelia M; Havekes Louis M; Frants Rune R; van Dijk Ko Willems; Smelt Augustinus H M
The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.
European journal of human genetics : EJHG 2009;17(5):620-8.
2009: Popa Calin; Netea Mihai G; de Graaf Jacqueline; van den Hoogen Frank H J; Radstake Timothy R D J; Toenhake-Dijkstra Helga; van Riel Piet L C M; van der Meer Jos W M; Stalenhoef Anton F H; Barrera Pilar
Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
The Journal of rheumatology 2009;36(4):724-30.
2009: Stalenhoef Anton F H
The benefit of statins in non-cardiac vascular surgery patients.
Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 2009;49(1):260-5.
2009: Jacobs Esther M G; Hendriks Jan C M; van Deursen Cees Th B M; Kreeftenberg Herman G; de Vries Richard A; Marx Joannes J M; Stalenhoef Anton F H; Verbeek André L M; Swinkels Dorine W
Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study.
Journal of hepatology 2009;50(1):174-83.
2009: Netea Mihai G; Joosten Leo A B; Keuter Monique; Wagener Frank; Stalenhoef Anton F H; van der Meer Jos W M; Kullberg Bart Jan
Circulating lipoproteins are a crucial component of host defense against invasive Salmonella typhimurium infection.
PloS one 2009;4(1):e4237.
2008: Koenen Tim B; van Tits Lambertus J H; Holewijn Suzanne; Lemmers Heidi L M; den Heijer Martin; Stalenhoef Anton F H; de Graaf Jacqueline
Adiponectin multimer distribution in patients with familial combined hyperlipidemia.
Biochemical and biophysical research communications 2008;376(1):164-8.
2008: Stalenhoef Anton F H; Watts Gerald F
Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008.
Atherosclerosis. Supplements 2008;9(2):1-2.
2008: van Himbergen Thomas M; van der Schouw Yvonne T; Voorbij Hieronymus A M; van Tits Lambertus J H; Stalenhoef Anton F H; Peeters Petra H M; Roest Mark
Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women.
Atherosclerosis 2008;199(2):408-14.
2008: van Himbergen Thomas M; van Tits Lambertus J H; Ter Avest Ewoud; Roest Mark; Voorbij Hieronymus A M; de Graaf Jacqueline; Stalenhoef Anton F H
Paraoxonase (PON1) is associated with familial combined hyperlipidemia.
Atherosclerosis 2008;199(1):87-94.
2008: Kastelein John J P; Akdim Fatima; Stroes Erik S G; Zwinderman Aeilko H; Bots Michiel L; Stalenhoef Anton F H; Visseren Frank L J; Sijbrands Eric J G; Trip Mieke D; Stein Evan A; Gaudet Daniel; Duivenvoorden Raphael; Veltri Enrico P; Marais A David; de Groot Eric;
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
The New England journal of medicine 2008;358(14):1431-43.
2008: Brouwers Martijn C G J; de Graaf Jacqueline; van Greevenbroek Marleen M J; Georgieva Anna M; van der Kallen Carla J H; Ter Avest Ewoud; Stehouwer Coen D A; Stalenhoef Anton F; de Bruin Tjerk W A
Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?
Clinical science (London, England : 1979) 2008;114(5):393-401.
2008: Diepeveen S H A; Wetzels J F M; Bilo H J G; van Tits L J H; Stalenhoef A F H
Cholesterol in end-stage renal disease: the good, the bad or the ugly?
The Netherlands journal of medicine 2008;66(2):53-61.
2008: Stalenhoef A F H
[Cardiovascular prevention in the over-80 age group is beneficial]
Nederlands tijdschrift voor geneeskunde 2008;152(1):26.
2008: Hoogendam Arjen; Stalenhoef Anton F H; Robbé Pieter F de Vries; Overbeke A John P M
Analysis of queries sent to PubMed at the point of care: observation of search behaviour in a medical teaching hospital.
BMC medical informatics and decision making 2008;8():42.
2007: Stalenhoef A F H; van Lith-Verhoeven J J C
Blurred vision.
The Netherlands journal of medicine 2007;65(11):461-2.
2007: Jacobs E M G; Hendriks J C M; Marx J J M; van Deursen C Th B M; Kreeftenberg H G; de Vries R A; Stalenhoef A F H; Verbeek A L M; Swinkels D W
Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS).
The Netherlands journal of medicine 2007;65(11):425-33.
2007: Jacobs E M G; Verbeek A L M; Kreeftenberg H G; van Deursen C Th B M; Marx J J M; Stalenhoef A F H; Swinkels D W; de Vries R A
Changing aspects of HFE-related hereditary haemochromatosis and endeavours to early diagnosis.
The Netherlands journal of medicine 2007;65(11):419-24.
2007: Popa Calin; van den Hoogen Frank H J; Radstake Timothy R D J; Netea Mihai G; Eijsbouts Agnes E; den Heijer Martin; van der Meer Jos W M; van Riel Piet L C M; Stalenhoef Anton F H; Barrera Pilar
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
Annals of the rheumatic diseases 2007;66(11):1503-7.
2007: Ferwerda Bart; McCall Matthew B B; Alonso Santos; Giamarellos-Bourboulis Evangelos J; Mouktaroudi Maria; Izagirre Neskuts; Syafruddin Din; Kibiki Gibson; Cristea Tudor; Hijmans Anneke; Hamann Lutz; Israel Shoshana; ElGhazali Gehad; Troye-Blomberg Marita; Kumpf Oliver; Maiga Boubacar; Dolo Amagana; Doumbo Ogobara; Hermsen Cornelus C; Stalenhoef Anton F H; van Crevel Reinout; Brunner Han G; Oh Djin-Ye; Schumann Ralf R; de la Rúa Concepcion; Sauerwein Robert; Kullberg Bart-Jan; van der Ven André J A M; van der Meer Jos W M; Netea Mihai G
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(42):16645-50.
2007: van Tits L J H; Jacobs E M G; Swinkels D W; Lemmers H L M; van der Vleuten G M; de Graaf J; Stalenhoef A F H
Non-transferrin-bound iron is associated with plasma level of soluble intercellular adhesion molecule-1 but not with in vivo low-density lipoprotein oxidation.
Atherosclerosis 2007;194(1):272-8.
2007: Ros M M; Sterk S S; Verhagen H; Stalenhoef A F H; de Jong N
Phytosterol consumption and the anabolic steroid boldenone in humans: a hypothesis piloted.
Food additives and contaminants 2007;24(7):679-84.
2007: Stalenhoef A F H
[Statins available from chemist shops will not positively affect health]
Nederlands tijdschrift voor geneeskunde 2007;151(25):1405.
2007: Hommels M J; Kroon A A; Netea M G; de Leeuw P W; Bruggeman C A; Leiner T; Koster D A; Stalenhoef A F H; van der Ven A J A M
The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis.
The Netherlands journal of medicine 2007;65(6):203-7.
2007: Bergmans J P H; Kemna E H J M; Janssen M C H; Jacobs E M G; Stalenhoef A F H; Marx J J M; Swinkels D W
[Hereditary haemochromatosis: novel genes, novel diseases and hepcidin]
Nederlands tijdschrift voor geneeskunde 2007;151(20):1121-7.
2007: Ter Avest E; Holewijn S; van Tits L J H; de Wit H M; Stalenhoef A F H; de Graaf J
Endothelial function in familial combined hyperlipidaemia.
European journal of clinical investigation 2007;37(5):381-9.
2007: Ter Avest Ewoud; Stalenhoef Anton F H; de Graaf Jacqueline
What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction?
Clinical science (London, England : 1979) 2007;112(10):507-16.
2007: van Tits Lambertus J H; van Heerde Waander L; van der Vleuten Gerly M; de Graaf Jacqueline; Grobbee Diederick E; van de Vijver Lucy P L; Stalenhoef Anton F; Princen Hans M
Plasma annexin A5 level relates inversely to the severity of coronary stenosis.
Biochemical and biophysical research communications 2007;356(3):674-80.
2007: van Lieshout Antoine W T; Popa Calin; Meyer-Wentrup Friederike; Lemmers Heidi L; Stalenhoef Anton F; Adema Gosse J; van Riel Piet L C M; van Tits Lambertus J; Radstake Timothy R D J
Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis.
Biochemical and biophysical research communications 2007;355(2):392-7.
2007: de Graaf Jacqueline; van der Vleuten Gerly M; ter Avest Ewoud; Dallinga-Thie Geesje M; Stalenhoef Anton F H
High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia.
The Journal of clinical endocrinology and metabolism 2007;92(4):1269-75.
2007: Popa Calin; Netea Mihai G; van Riel Piet L C M; van der Meer Jos W M; Stalenhoef Anton F H
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
Journal of lipid research 2007;48(4):751-62.
2007: ter Avest Ewoud; Holewijn Suzanne; Bredie Sebastian J H; van Tits Lambertus J H; Stalenhoef Anton F H; de Graaf Jacqueline
Pulse wave velocity in familial combined hyperlipidemia.
American journal of hypertension 2007;20(3):263-9.
2007: ter Avest Ewoud; Holewijn Suzanne; Bredie Sebastian J H; Stalenhoef Anton F H; de Graaf Jacqueline
Remnant particles are the major determinant of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH).
Atherosclerosis 2007;191(1):220-6.
2007: van der Vleuten Gerly M; Isaacs Aaron; Zeng Wu-Wei; ter Avest Ewoud; Talmud Philippa J; Dallinga-Thie Geesje M; van Duijn Cornelia M; Stalenhoef Anton F H; de Graaf Jacqueline
Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.
Biochimica et biophysica acta 2007;1772(1):81-8.
2007: van der Vleuten Gerly M; Isaacs Aaron; Hijmans Anneke; van Duijn Cornelia M; Stalenhoef Anton F H; de Graaf Jacqueline
The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia.
Journal of lipid research 2007;48(1):193-200.
2007: ter Avest Ewoud; Sniderman Allan D; Bredie Sebastian J H; Wiegman Albert; Stalenhoef Anton F H; de Graaf Jacqueline
Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.
Clinical science (London, England : 1979) 2007;112(2):131-9.
2006: Stalenhoef A F H
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure]
Nederlands tijdschrift voor geneeskunde 2006;150(39):2127-30.
2006: van Aalst-Cohen Emily S; Jansen Angelique C M; Tanck Michael W T; Defesche Joep C; Trip Mieke D; Lansberg Peter J; Stalenhoef Anton F H; Kastelein John J P
Diagnosing familial hypercholesterolaemia: the relevance of genetic testing.
European heart journal 2006;27(18):2240-6.
2006: Drenth J P H; Smits P; Thien T; Stalenhoef A F H
The case for case reports in the Netherlands Journal of Medicine.
The Netherlands journal of medicine 2006;64(7):262-4.
2006: Netea Mihai G; Joosten Leo A B; Lewis Eli; Jensen Dalan R; Voshol Peter J; Kullberg Bart Jan; Tack Cees J; van Krieken Han; Kim Soo-Hyun; Stalenhoef Anton F; van de Loo Fons A; Verschueren Ineke; Pulawa Leslie; Akira Shizuo; Eckel Robert H; Dinarello Charles A; van den Berg Wim; van der Meer Jos W M
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance.
Nature medicine 2006;12(6):650-6.
2006: Vermeulen S H H M; van der Vleuten G M; de Graaf J; Hermus A R; Blom H J; Stalenhoef A F H; den Heijer M
A genome-wide linkage scan for homocysteine levels suggests three regions of interest.
Journal of thrombosis and haemostasis : JTH 2006;4(6):1303-7.
2006: van Tits Lambertus J H; Jacobs Esther M G; Swinkels Dorine W; Lemmers Heidi L M; van der Vleuten Gerly M; de Graaf Jacqueline; Stalenhoef Anton F H
Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis.
Biochemical and biophysical research communications 2006;345(1):371-6.
2006: van der Vleuten G M; Kluijtmans L A; Hijmans A; Blom H J; Stalenhoef A F H; de Graaf J
The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia.
International journal of obesity (2005) 2006;30(6):892-8.
2006: van der Vleuten Gerly M; Hijmans Anneke; Heil Sandra; Blom Henk J; Stalenhoef Anton F H; de Graaf Jacqueline
Can we exclude the TXNIP gene as a candidate gene for familial combined hyperlipidemia?
American journal of medical genetics. Part A 2006;140(9):1010-2.
2006: van Tits L J H; van Himbergen T M; Lemmers H L M; de Graaf J; Stalenhoef A F H
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
Atherosclerosis 2006;185(2):307-12.
2006: van Himbergen T M; van Tits L J H; Roest M; Stalenhoef A F H
The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine.
The Netherlands journal of medicine 2006;64(2):34-8.
2006: de Bont Natasja; Netea Mihai G; Rovers Chantal; Smilde Tineke; Hijmans Anneke; Demacker Pierre N M; van der Meer Jos W M; Stalenhoef Anton F H
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006;26(2):101-7.
2006: van den Nieuwenhoff Hélène W P; Mesters Ilse; Nellissen Joyce J T M; Stalenhoef Anton F; de Vries Nanne K
The importance of written information packages in support of case-finding within families at risk for inherited high cholesterol.
Journal of genetic counseling 2006;15(1):29-40.
2006: Walma E P; Visseren F L J; Jukema J W; Kastelein J J P; Hoes A W; Stalenhoef A F H
[The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board]
Nederlands tijdschrift voor geneeskunde 2006;150(1):18-23.
2006: Abbink E J; De Graaf J; De Haan J H; Heerschap A; Stalenhoef A F; Tack C J
Effects of pioglitazone in familial combined hyperlipidaemia.
Journal of internal medicine 2006;259(1):107-16.
2005: Drenth J P H; Smits P; Thien T; Stalenhoef A F H
The Netherlands Journal of Medicine's hit list: best cited articles in 2003.
The Netherlands journal of medicine 2005;63(11):418-20.
2005: van der Vleuten Gerly M; Veerkamp Mario J; van Tits Lambertus J H; Toenhake Helga; den Heijer Martin; Stalenhoef Anton F H; de Graaf Jacqueline
Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD.
Atherosclerosis 2005;183(2):355-60.
2005: Stalenhoef Anton F H; Ballantyne Christie M; Sarti Cinzia; Murin Jan; Tonstad Serena; Rose Helen; Wilpshaar Wim
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
European heart journal 2005;26(24):2664-72.
2005: Himbergen T M; van Tits L J H; Voorbij H A M; de Graaf J; Stalenhoef A F H; Roest M
The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Journal of internal medicine 2005;258(5):442-9.
2005: Diepeveen Sabine H A; Verhoeven Gertie H W E; van der Palen Job; Dikkeschei Bert L D; van Tits Berry L J; Kolsters Geert; Offerman Joop J G; Bilo Henk J G; Stalenhoef Anton F H
The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment.
Clinica chimica acta; international journal of clinical chemistry 2005;361(1-2):112-8.
2005: van der Vleuten Gerly M; van Tits Lambertus J H; den Heijer Martin; Lemmers Heidi; Stalenhoef Anton F H; de Graaf Jacqueline
Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile.
Journal of lipid research 2005;46(11):2398-404.
2005: Popa Calin; Barrea Pilar; Netea Mihai G; Stalenhoef Anton F H; van der Meer Jos W M
Anti-TNF therapy and plasma HDL cholesterol concentration.
Atherosclerosis 2005;182(2):375; author reply 377.
2005: ter Avest Ewoud; Abbink Evertine J; Holewijn Suzanne; de Graaf Jacqueline; Tack Cees J; Stalenhoef Anton F H
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).
Current medical research and opinion 2005;21(9):1469-76.
2005: ter Avest E; Abbink E J; de Graaf J; Tack C J; Stalenhoef A F H
Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia.
European journal of clinical investigation 2005;35(9):558-64.
2005: Hovingh G Kees; Hutten Barbara A; Holleboom Adriaan G; Petersen Wilma; Rol Patrick; Stalenhoef Anton; Zwinderman Aeilko H; de Groot Eric; Kastelein John J P; Kuivenhoven Jan Albert
Compromised LCAT function is associated with increased atherosclerosis.
Circulation 2005;112(6):879-84.
2005: van Himbergen Thomas M; van Tits Lambertus J H; Hectors Magda P C; de Graaf Jacqueline; Roest Mark; Stalenhoef Anton F H
Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia.
Biochemical and biophysical research communications 2005;333(3):787-93.
2005: van Tits L J H; Arioglu-Oral E; Sweep C G J; Smits P; Stalenhoef A F H; Tack C J
Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
The Netherlands journal of medicine 2005;63(7):250-5.
2005: van Tits Lambertus J; de Graaf Jacqueline; Stalenhoef Anton F
Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial".
Circulation 2005;111(18):e284-5; author reply e284-5.
2005: Diepeveen S H A; Verhoeven G W H E; Van Der Palen J; Dikkeschei L D; Van Tits L J; Kolsters G; Offerman J J G; Bilo H J G; Stalenhoef A F H
Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Journal of internal medicine 2005;257(5):438-45.
2005: Stalenhoef Anton F H
Management of mixed hyperlipidaemia.
European heart journal 2005;26(9):856-7.
2005: Veerkamp M J; de Graaf J; Stalenhoef A F H
Role of insulin resistance in familial combined hyperlipidemia.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(5):1026-31.
2005: ter Avest Ewoud; Holewijn Suzanne; Stalenhoef Anton F H; de Graaf Jacqueline
Variation in non-invasive measurements of vascular function in healthy volunteers during daytime.
Clinical science (London, England : 1979) 2005;108(5):425-31.
2005: van Tits Lambertus; de Graaf Jacqueline; Toenhake Helga; van Heerde Waander; Stalenhoef Anton
C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(4):717-22.
2005: van Himbergen Thomas M; Roest Mark; de Graaf Jacqueline; Jansen Eugène H J M; Hattori Hiroaki; Kastelein John J P; Voorbij Hieronymus A M; Stalenhoef Anton F H; van Tits Lambertus J H
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia.
Journal of lipid research 2005;46(3):445-51.
2005: Popa C; Netea M G; Radstake T; Van der Meer J W M; Stalenhoef A F H; van Riel P L C M; Barerra P
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Annals of the rheumatic diseases 2005;64(2):303-5.
2005: van Wissen Sanne; Smilde Tineke J; Trip Mieke D; Stalenhoef Anton F H; Kastelein John J P
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
The American journal of cardiology 2005;95(2):264-6.
2004: Soetevent C; Klemm P L; Stalenhoef A F H; Bredie S J H
Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment.
The Netherlands journal of medicine 2004;62(11):446-52.
2004: de Grooth Greetje J; Klerkx Anke H E M; Stroes Erik S G; Stalenhoef Anton F H; Kastelein John J P; Kuivenhoven Jan Albert
A review of CETP and its relation to atherosclerosis.
Journal of lipid research 2004;45(11):1967-74.
2004: van der Vleuten Gerly M; Hijmans Anneke; Kluijtmans Leo A J; Blom Henk J; Stalenhoef Anton F H; de Graaf Jacqueline
Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemia.
American journal of medical genetics. Part A 2004;130A(1):73-5.
2004: de Graaf Jacqueline; van der Vleuten Gerly; Stalenhoef Anton F H
Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia.
Seminars in vascular medicine 2004;4(3):229-40.
2004: Vonk Alieke G; De Bont Natasja; Netea Mihai G; Demacker Pierre N M; van der Meer Jos W M; Stalenhoef Anton F H; Kullberg Bart Jan
Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2004;42(4):341-8.
2004: Goettsch Wim G; Yin Donald D; Alemao Evo; Klungel Olaf H; Stalenhoef Anton F; Herings Ron M C
Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study.
Current medical research and opinion 2004;20(7):1025-33.
2004: Netea Mihai G; Kullberg Bart Jan; Jacobs Liesbeth E H; Verver-Jansen Trees J G; van der Ven-Jongekrijg Johanna; Galama Jochem M D; Stalenhoef Anton F H; Dinarello Charles A; Van der Meer Jos W M
Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(2):1477-82.
2004: Van Himbergen Thomas; Roest Mark; De Waart Frouwkje; De Graaf Jacqueline; Voorbij Hieronymus; Van Tits Lambertus; Stalenhoef Anton
Paraoxonase genotype, LDL-oxidation and carotid atherosclerosis in male life-long smokers.
Free radical research 2004;38(6):553-60.
2004: Veerkamp Mario J; de Graaf Jacqueline; Hendriks Jan C M; Demacker Pierre N M; Stalenhoef Anton F H
Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study.
Circulation 2004;109(24):2980-5.
2004: Simon Anna; Drewe Elizabeth; van der Meer Jos W M; Powell Richard J; Kelley Richard I; Stalenhoef Anton F H; Drenth Joost P H
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Clinical pharmacology and therapeutics 2004;75(5):476-83.
2004: van Tits Lambertus J H; Smilde Tineke J; van Wissen Sanne; de Graaf Jacqueline; Kastelein John J P; Stalenhoef Anton F H
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(3):177-84.
2004: de Grooth Greetje J; Smilde Tineke J; Van Wissen Sanne; Klerkx Anke H E M; Zwinderman Aeilko H; Fruchart Jean-Charles; Kastelein John J P; Stalenhoef Anton F H; Kuivenhoven Jan Albert
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Atherosclerosis 2004;173(2):261-7.
2004: Sprong Tom; Netea Mihai G; van der Ley Peter; Verver-Jansen Trees J G; Jacobs Liesbeth E H; Stalenhoef Anton; van der Meer Jos W M; van Deuren Marcel
Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria.
Journal of lipid research 2004;45(4):742-9.
2004: Rodenburg J; Wiegman A; Vissers M N; Kastelein J J P; Stalenhoef A F H
A boy with autosomal recessive hypercholesterolaemia.
The Netherlands journal of medicine 2004;62(3):89-93.
2004: Netea M G; Hijmans A; van Wissen S; Smilde T J; Trip M D; Kullberg B J; de Boo T; Van der Meer J W M; Kastelein J J P; Stalenhoef A F H;
Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia.
European journal of clinical investigation 2004;34(2):94-9.
2004: Diepeveen Sabine H A; Verhoeven Gertie H W E; van der Palen Job; Dikkeschei Bert L D; van Tits Lambertus J; Kolsters Geert; Offerman Joop J G; Bilo Henk J G; Stalenhoef Anton F H
Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy.
Nephron. Clinical practice 2004;98(1):c3-7.
2003: van Wissen Sanne; Smilde Tineke J; de Groot Eric; Hutten Barbara A; Kastelein John J P; Stalenhoef Anton F H
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2003;10(6):451-5.
2003: van Wissen S; Smilde T J; Trip M D; de Boo Th; Kastelein J J P; Stalenhoef A F H
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Heart (British Cardiac Society) 2003;89(8):893-6.
2003: Stalenhoef Anton F
Images in clinical medicine. Phytosterolemia and xanthomatosis.
The New England journal of medicine 2003;349(1):51.
2003: Jacobs E M G; de Vries R A; Elving L D; Stalenhoef A F H; Swinkels D W
[Diagnosis of 5 patients with possible primary hemochromatosis]
Nederlands tijdschrift voor geneeskunde 2003;147(14):666-70.
2003: Ginsberg Henry N; Stalenhoef Anton F H
The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
Journal of cardiovascular risk 2003;10(2):121-8.
2003: van den Akker Judith M; Bredie Sebastian J H; Diepenveen Sabine H A; van Tits Lambertus J H; Stalenhoef Anton F H; van Leusen Rob
Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
Journal of nephrology 2003;16(2):238-44.
2003: Trip Mieke D; van Wissen Sanne; Smilde Tineke J; Hutten Barbara A; Stalenhoef Anton F H; Kastelein John J P
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
The American journal of cardiology 2003;91(5):604-6.
2003: van Tits Lambertus J H; de Waart Frouwkje; Hak-Lemmers Heidi L M; de Graaf Jacqueline; Demacker Pierre N M; Stalenhoef Anton F H
Neutrophil superoxide-anion generating capacity in chronic smoking: effect of long-term alpha-tocopherol therapy.
Journal of biosciences 2003;28(1):23-7.
2003: Semb Anne G; van Wissen Sanne; Ueland Thor; Smilde Tineke; Waehre Torgun; Tripp Mieke D; Frøland Stig S; Kastelein John J P; Gullestad Lars; Pedersen Terje R; Aukrust Pål; Stalenhoef Anton F H
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Journal of the American College of Cardiology 2003;41(2):275-9.
2003: Van Tits Lambertus; De Graaf Jacqueline; Hak-Lemmers Heidi; Bredie Sebastian; Demacker Pierre; Holvoet Paul; Stalenhoef Anton
Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis.
Laboratory investigation; a journal of technical methods and pathology 2003;83(1):13-21.
2003: Veerkamp M J; de Graaf J; den Heijer M; Blom H J; Stalenhoef A F H
Plasma homocysteine in subjects with familial combined hyperlipidemia.
Atherosclerosis 2003;166(1):111-7.
2002: van der Meer J W M; Stalenhoef A F H; Smits P; Thien Th
Abstract!
The Netherlands journal of medicine 2002;60(11):418.
2002: van Wissen Sanne; Trip Mieke D; Smilde Tineke J; de Graaf Jacqueline; Stalenhoef Anton F H; Kastelein John J P
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Atherosclerosis 2002;165(2):361-6.
2002: Bredie S J H; Wollersheim H C H; Lenders J W M; Stalenhoef A F H
[The added value of a structured evaluation of patients with vascular disease]
Nederlands tijdschrift voor geneeskunde 2002;146(48):2277-81.
2002: De Graaf Jacqueline; De Sauvage Nolting Pernette R W; Van Dam Marjel; Belsey Elizabeth M; Kastelein John J P; Haydn Pritchard P; Stalenhoef Anton F H
Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels.
The British journal of nutrition 2002;88(5):479-88.
2002: Attie Alan D; Krauss Ronald M; Gray-Keller Mark P; Brownlie Alison; Miyazaki Makoto; Kastelein John J; Lusis Aldons J; Stalenhoef Anton F H; Stoehr Jonathan P; Hayden Michael R; Ntambi James M
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia.
Journal of lipid research 2002;43(11):1899-907.
2002: Stalenhoef A F H; Stuyt P M J
[Broader indication for treatment with statins; the 'heart protection study']
Nederlands tijdschrift voor geneeskunde 2002;146(41):1921-3.
2002: Stalenhoef Anton F H
Interaction between genes and environment in inherited lipid disorders determines clinical presentation.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2002;16(4):271-2.
2002: Netea Mihai G; Kullberg Bart Jan; Demacker Pierre N M; Jacobs Liesbeth E H; Verver-Jansen Trees J G; Hijmans Anneke; van Tits Lambertus H J; Hoenderop Joost G J; Willems Peter H G M; Van der Meer Jos W M; Stalenhoef Anton F H
Native LDL potentiate TNF alpha and IL-8 production by human mononuclear cells.
Journal of lipid research 2002;43(7):1065-71.
2002: de Grooth Greetje J; Kuivenhoven Jan Albert; Stalenhoef Anton F H; de Graaf Jacqueline; Zwinderman Aeilko H; Posma Jan L; van Tol Arie; Kastelein John J P
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Circulation 2002;105(18):2159-65.
2002: Netea Mihai G; Kullberg Bart Jan; Galama Jochem M D; Stalenhoef Anton F H; Dinarello Charles A; Van der Meer Jos W M
Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways.
European journal of immunology 2002;32(4):1188-95.
2002: de Beer Femke; Stalenhoef Anton F H; Hoogerbrugge Nicoline; Kastelein John J P; Gevers Leuven Jan A; van Duijn Cornelia M; Havekes Louis M; Smelt Augustinus H M
Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(2):294-9.
2002: Veerkamp Mario J; de Graaf Jacqueline; Bredie Sebastian J H; Hendriks Jan C M; Demacker Pierre N M; Stalenhoef Anton F H
Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(2):274-82.
2002: de Graaf Jacqueline; Veerkamp Mario J; Stalenhoef Anton F H
Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.
Journal of the Royal Society of Medicine 2002;95 Suppl 42():46-53.
2001: Smilde T J; van Wissen S; Wollersheim H; Kastelein J J; Stalenhoef A F
Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia.
The Netherlands journal of medicine 2001;59(4):184-95.
2001: de Waart F G; Kok F J; Smilde T J; Hijmans A; Wollersheim H; Stalenhoef A F
Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers.
Atherosclerosis 2001;158(1):227-31.
2001: Bredie S J; Bosch F H; Demacker P N; Stalenhoef A F; van Leusen R
Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2001;21(3):275-81.
2001: van Tits L J; de Waart F; Hak-Lemmers H L; van Heijst P; de Graaf J; Demacker P N; Stalenhoef A F
Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers.
Free radical biology & medicine 2001;30(10):1122-9.
2001: Smilde T J; van Wissen S; Wollersheim H; Trip M D; Kastelein J J; Stalenhoef A F
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Lancet 2001;357(9256):577-81.
2001: Stalenhoef A F; Hectors M; Demacker P N
Effect of plant sterol-enriched margarine on plasma lipids and sterols in subjects heterozygous for phytosterolaemia.
Journal of internal medicine 2001;249(2):163-6.
2001: De Waart F G; Schouten E G; Stalenhoef A F; Kok F J
Serum carotenoids, alpha-tocopherol and mortality risk in a prospective study among Dutch elderly.
International journal of epidemiology 2001;30(1):136-43.
2001: de Roos B; Caslake M J; Stalenhoef A F; Bedford D; Demacker P N; Katan M B; Packard C J
The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects.
The American journal of clinical nutrition 2001;73(1):45-52.
2000: Demacker P N; Veerkamp M J; Bredie S J; Marcovina S M; de Graaf J; Stalenhoef A F
Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia.
Atherosclerosis 2000;153(2):483-90.
2000: van den Berkmortel F W; Demacker P N; Wollersheim H; Thien T; Stalenhoef A F
Smoking or its cessation does not alter the susceptibility to in vitro LDL oxidation.
European journal of clinical investigation 2000;30(11):972-9.
2000: van Tits L J; Hak-Lemmers H L; Demacker P N; Stalenhoef A F; Willems P H
Oxidized low-density lipoprotein induces calcium influx in polymorphonuclear leukocytes.
Free radical biology & medicine 2000;29(8):747-55.
2000: Kroon A A; van't Hof M A; Demacker P N; Stalenhoef A F
The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
Atherosclerosis 2000;152(2):519-26.
2000: de Bont N; Netea M G; Demacker P N; Kullberg B J; van der Meer J W; Stalenhoef A F
Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae.
European journal of clinical investigation 2000;30(9):818-22.
2000: Hoffer M J; Snieder H; Bredie S J; Demacker P N; Kastelein J J; Frants R R; Stalenhoef A F
The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia.
Atherosclerosis 2000;151(2):443-50.
2000: de Waart F G; Smilde T J; Wollersheim H; Stalenhoef A F; Kok F J
Smoking characteristics, antioxidant vitamins, and carotid artery wall thickness among life-long smokers.
Journal of clinical epidemiology 2000;53(7):707-14.
2000: de Graaf J; Hoffer M J; Stuyt P M; Frants R R; Stalenhoef A F
Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCII gene and the first APOCIV gene mutation: APOCII-CIV(Nijmegen).
Biochemical and biophysical research communications 2000;273(3):1084-7.
2000: Smilde T J; van den Berkmortel F W; Wollersheim H; van Langen H; Kastelein J J; Stalenhoef A F
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
European journal of clinical investigation 2000;30(6):473-80.
2000: de Graaf J; Stalenhoef A F
[Use of margarine fortified with phytosterols as a therapeutic food]
Nederlands tijdschrift voor geneeskunde 2000;144(20):918-21.
2000: Demacker P N; Hectors M P; Stalenhoef A F
Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A and E as markers: a new physiological concept.
Atherosclerosis 2000;149(1):169-80.
2000: Stalenhoef A F
['Cholesterol' guidelines (first revision) of the Dutch College of Family Physicians; response from internal medicine]
Nederlands tijdschrift voor geneeskunde 2000;144(9):407-9.
2000: Netea M G; Selzman C H; Kullberg B J; Galama J M; Weinberg A; Stalenhoef A F; Van der Meer J W; Dinarello C A
Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells.
European journal of immunology 2000;30(2):541-9.
2000: van Tits L J; Demacker P N; de Graaf J; Hak-Lemmers H L; Stalenhoef A F
alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals.
The American journal of clinical nutrition 2000;71(2):458-64.
1999: Stalenhoef A F
Management of serum lipid levels into the next millennium: new targets for treatment.
The Netherlands journal of medicine 1999;55(6):300-3.
1999: Kroon A A; Demacker P N; Kleinveld H A; Stalenhoef A F
The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability.
Atherosclerosis 1999;147(1):105-13.
1999: de Bont N; Geijtenbeek T B; Netea M G; Smilde T J; Demacker P N; Figdor C G; Van Der Meer J W; Stalenhoef A F
Integrin mediated adhesion of mononuclear cells from patients with familial hypercholesterolemia.
European journal of clinical investigation 1999;29(9):749-57.
1999: Netea R T; Netea M G; Bredie S J; Demacker P N; Hancu N; Thien T; Stalenhoef A F
Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension.
The Netherlands journal of medicine 1999;55(1):39-45.
1999: de Bont N; Netea M G; Demacker P N; Verschueren I; Kullberg B J; van Dijk K W; van der Meer J W; Stalenhoef A F
Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection.
Journal of lipid research 1999;40(4):680-5.
1998: Demacker P N; Bredie S J; Hectors M P; Stalenhoef A F
Fat loading experiments with the vitamins A and E suggest that in postprandial lipemia transfer/diffusion of chylomicron lipids to VLDL contributes to beta-VLDL formation.
Atherosclerosis 1998;141 Suppl 1():S109-13.
1998: Smilde T J; van den Berkmortel F W; Boers G H; Wollersheim H; de Boo T; van Langen H; Stalenhoef A F
Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(12):1958-63.
1998: Rovers C; Netea M G; de Bont N; Demacker P N; Jacobs C; Kullberg B J; Van der Meer J W; Stalenhoef A F
LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia.
Atherosclerosis 1998;141(1):99-105.
1998: Stuyt P M; Kleinjans H A; Stalenhoef A F
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
The Netherlands journal of medicine 1998;53(5):228-33.
1998: Netea M G; Demacker P N; Kullberg B J; Boerman O C; Verschueren I; Stalenhoef A F; Van Der Meer J W
Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated.
Immunology 1998;95(3):466-72.
1998: Netea M G; Demacker P N; Kullberg B J; Jacobs L E; Verver-Jansen T J; Boerman O C; Stalenhoef A F; Van der Meer J W
Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur.
Cytokine 1998;10(10):766-72.
1998: de Bont N; Netea M G; Rovers C; Smilde T; Demacker P N; van der Meer J W; Stalenhoef A F
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Atherosclerosis 1998;139(1):147-52.
1998: Demacker P N; Bredie S J; Vogelaar J M; Hectors M P; van Heijst P; Stuyt P M; Stalenhoef A F
Beta-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins.
Atherosclerosis 1998;138(2):301-12.
1998: de Graaf J; Stalenhoef A F
Defects of lipoprotein metabolism in familial combined hyperlipidaemia.
Current opinion in lipidology 1998;9(3):189-96.
1998: Hoffer M J; Bredie S J; Snieder H; Reymer P W; Demacker P N; Havekes L M; Boomsma D I; Stalenhoef A F; Frants R R; Kastelein J J
Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia.
Atherosclerosis 1998;138(1):91-9.
1998: Diekman T; Demacker P N; Kastelein J J; Stalenhoef A F; Wiersinga W M
Increased oxidizability of low-density lipoproteins in hypothyroidism.
The Journal of clinical endocrinology and metabolism 1998;83(5):1752-5.
1998: Netea M G; de Bont N; Demacker P N; Kullberg B J; Jacobs L E; Verver-Jansen T J; Stalenhoef A F; Van der Meer J W
Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells.
Infection and immunity 1998;66(5):2365-7.
1997: Smilde T J; Wollersheim H; Van Langen H; Stalenhoef A F
Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness.
Clinical science (London, England : 1979) 1997;93(4):317-24.
1997: Bredie S J; Demacker P N; Stalenhoef A F
Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity.
European journal of clinical investigation 1997;27(10):802-11.
1997: Stalenhoef A F; Kroon A A; Aengevaeren W R
Aggressive lipid lowering treatment in coronary atherosclerosis.
Cardiologia (Rome, Italy) 1997;42(9):935-40.
1997: Bredie S J; Tack C J; Smits P; Stalenhoef A F
Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(7):1465-71.
1997: Kroon A A; Stalenhoef A F
LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update.
The Netherlands journal of medicine 1997;51(1):16-27.
1997: Stalenhoef A F; Stuyt P M; de Graaf J
Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.
The Netherlands journal of medicine 1997;51(1):10-5.
1997: Netea M G; Demacker P N; de Bont N; Boerman O C; Stalenhoef A F; van der Meer J W; Kullberg B J
Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice.
Infection and immunity 1997;65(7):2663-7.
1997: Bredie S J; van Drongelen J; Kiemeney L A; Demacker P N; Beaty T H; Stalenhoef A F
Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(5):834-40.
1997: Mol M J; de Rijke Y B; Demacker P N; Stalenhoef A F
Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment.
Atherosclerosis 1997;129(2):169-76.
1997: de Rijke Y B; Bredie S J; Demacker P N; Vogelaar J M; Hak-Lemmers H L; Stalenhoef A F
The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(1):127-33.
1996: Aengevaeren W R; Kroon A A; Stalenhoef A F; Uijen G J; van der Werf T
Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).
Journal of the American College of Cardiology 1996;28(7):1696-704.
1996: Bredie S J; Vogelaar J M; Demacker P N; Stalenhoef A F
Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia.
Atherosclerosis 1996;126(2):313-24.
1996: Bredie S J; Westerveld H T; Knipscheer H C; de Bruin T W; Kastelein J J; Stalenhoef A F
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
The Netherlands journal of medicine 1996;49(2):59-67.
1996: Kroon A A; Aengevaeren W R; van der Werf T; Uijen G J; Reiber J H; Bruschke A V; Stalenhoef A F
LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.
Circulation 1996;93(10):1826-35.
1996: Bredie S J; Kiemeney L A; de Haan A F; Demacker P N; Stalenhoef A F
Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.
American journal of human genetics 1996;58(4):812-22.
1996: Netea M G; Demacker P N; Kullberg B J; Boerman O C; Verschueren I; Stalenhoef A F; van der Meer J W
Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.
The Journal of clinical investigation 1996;97(6):1366-72.
1995: Kroon A A; Ajubi N; van Asten W N; Stalenhoef A F
The prevalence of peripheral vascular disease in familial hypercholesterolaemia.
Journal of internal medicine 1995;238(5):451-9.
1995: Hilbrands L B; Demacker P N; Hoitsma A J; Stalenhoef A F; Koene R A
The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.
Journal of the American Society of Nephrology : JASN 1995;5(12):2073-81.
1995: Knops R E; Kroon A A; Mol M J; Stuyt P M; Stalenhoef A F
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.
The Netherlands journal of medicine 1995;46(4):171-8.
1995: Stalenhoef A F; Armstrong V W; Steinmetz A; Taskinen M R; Zechner R
The 17th annual meeting of the European Lipoprotein Club.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(4):543-9.
1995: Bredie S J; de Bruin T W; Demacker P N; Kastelein J J; Stalenhoef A F
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
The American journal of cardiology 1995;75(5):348-53.
1995: Kleinveld H A; Hak-Lemmers H L; Hectors M P; de Fouw N J; Demacker P N; Stalenhoef A F
Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(2):290-7.
1994: Kroon A A; Swinkels D W; van Dongen P W; Stalenhoef A F
Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis.
Metabolism: clinical and experimental 1994;43(9):1164-70.
1994: Kleinveld H A; Demacker P N; Stalenhoef A F
Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(8):1386-91.
1994: Stalenhoef A F; Defesche J C; Kleinveld H A; Demacker P N; Kastelein J J
Decreased resistance against in vitro oxidation of LDL from patients with familial defective apolipoprotein B-100.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(3):489-93.
1993: de Graaf J; Demacker P N; Stalenhoef A F
The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
The Netherlands journal of medicine 1993;43(5-6):254-61.
1993: Kroon A A; Stalenhoef A F; Buikema H; Demacker P N; de Wilde P C; Leijten P A; van Gilst W H
The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.
Atherosclerosis 1993;103(2):221-30.
1993: Kleinveld H A; Naber A H; Stalenhoef A F; Demacker P N
Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects.
Free radical biology & medicine 1993;15(3):273-80.
1993: Demacker P N; Hijmans A G; Kleinveld H A; Stalenhoef A F
Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants.
Atherosclerosis 1993;102(1):69-77.
1993: Mol M J; Demacker P N; Stalenhoef A F
The role of modification of lipoproteins and of the immune system in early atherogenesis.
The Netherlands journal of medicine 1993;43(1-2):83-90.
1993: Stalenhoef A F; Lansberg P J; Kroon A A; Kortmann B; De Haan A F; Stuyt P M; Kastelein J J
Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Journal of internal medicine 1993;234(1):77-82.
1993: de Graaf J; Hendriks J C; Demacker P N; Stalenhoef A F
Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(5):712-9.
1993: Kleinveld H A; Demacker P N; De Haan A F; Stalenhoef A F
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
European journal of clinical investigation 1993;23(5):289-95.
1993: de Graaf J; Swinkels D W; Demacker P N; de Haan A F; Stalenhoef A F
Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls.
The Journal of clinical endocrinology and metabolism 1993;76(1):197-202.
1993: de Graaf J; Hendriks J C; Swinkels D W; Demacker P N; Stalenhoef A F
Differences in LDL receptor-mediated metabolism of three low density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis.
Artery 1993;20(4):201-30.
1992: de Graaf J; Swinkels D W; de Haan A F; Demacker P N; Stalenhoef A F
Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families.
American journal of human genetics 1992;51(6):1295-310.
1992: Kroon A A; Mol M J; Stalenhoef A F
ACE inhibitors and LDL-apheresis with dextran sulphate adsorption.
Lancet 1992;340(8833):1476.
1992: Kleinveld H A; Hak-Lemmers H L; Stalenhoef A F; Demacker P N
Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein.
Clinical chemistry 1992;38(10):2066-72.
1992: Demacker P N; van Heijst P J; Stalenhoef A F
A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate.
The Biochemical journal 1992;285 ( Pt 2)():641-6.
1992: Kleinveld H A; Demacker P N; Stalenhoef A F
Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects.
European journal of clinical pharmacology 1992;43(6):639-42.
1991: Kroon A A; Demacker P N; Stalenhoef A F
N-acetylcysteine and serum concentrations of lipoprotein(a).
Journal of internal medicine 1991;230(6):519-26.
1991: Demacker P N; Staels B; Stalenhoef A F; Auwerx J
Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(6):1652-9.
1991: Stuyt P M; Brenninkmeijer B J; Demacker P N; Hendriks J C; van Elteren P; Stalenhoef A F; van 't Laar A
Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease.
Scandinavian journal of clinical and laboratory investigation 1991;51(5):425-35.
1991: Mol M J; Stalenhoef A F; Demacker P N; van 't Laar A
Alterations in the metabolism of very-low- and low-density lipoproteins after partial ileal-bypass surgery in the Watanabe heritable hyperlipidaemic rabbit.
The Biochemical journal 1991;278 ( Pt 3)():651-7.
1991: Stuyt P M; Mol M J; Stalenhoef A F
Long-term effects of simvastatin in familial dysbetalipoproteinaemia.
Journal of internal medicine 1991;230(2):151-5.
1991: Dormans T P; Swinkels D W; de Graaf J; Hendriks J C; Stalenhoef A F; Demacker P N
Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared.
Clinical chemistry 1991;37(6):853-8.
1991: van Dusseldorp M; Katan M B; van Vliet T; Demacker P N; Stalenhoef A F
Cholesterol-raising factor from boiled coffee does not pass a paper filter.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(3):586-93.
1991: Demacker P N; Reijnen I G; Katan M B; Stuyt P M; Stalenhoef A F
Increased removal of remnants of triglyceride-rich lipoproteins on a diet rich in polyunsaturated fatty acids.
European journal of clinical investigation 1991;21(2):197-203.
1991: de Graaf J; Hak-Lemmers H L; Hectors M P; Demacker P N; Hendriks J C; Stalenhoef A F
Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1991;11(2):298-306.
1990: Demacker P N; Mol M J; Stalenhoef A F
Increased hepatic lipase activity and increased direct removal of very-low-density lipoprotein remnants in Watanabe heritable hyperlipidaemic (WHHL) rabbits treated with ethinyl oestradiol.
The Biochemical journal 1990;272(3):647-51.
1990: Swinkels D W; Hendriks J C; Demacker P N; Stalenhoef A F
Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells.
Biochimica et biophysica acta 1990;1047(3):212-22.
1990: De Knijff P; Stalenhoef A F; Mol M J; Gevers Leuven J A; Smit J; Erkelens D W; Schouten J; Frants R R; Havekes L M
Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.
Atherosclerosis 1990;83(1):89-97.
1990: Mol M J; Stalenhoef A F
Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis.
The Netherlands journal of medicine 1990;36(5-6):279-87.
1990: Mol M J; Stuyt P M; Demacker P N; Stalenhoef A F
The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
The Netherlands journal of medicine 1990;36(3-4):182-90.
1990: Stuyt P M; Mol M J; Stalenhoef A F; Demacker P N; Van 't Laar A
Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).
The American journal of medicine 1990;88(1N):42N-45N.
1989: Mol M J; Stalenhoef A F; Stuyt P M; Hermus A R; Demacker P N; Van 'T Laar A
Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH.
Clinical endocrinology 1989;31(6):679-89.
1989: Stalenhoef A F; Mol M J; Stuyt P M
Efficacy and tolerability of simvastatin (MK-733).
The American journal of medicine 1989;87(4A):39S-43S.
1989: Mol M J; Stalenhoef A F; Demacker P N; van't Laar A
Low-density lipoprotein catabolism in WHHL rabbits after partial ileal bypass surgery.
Biochimica et biophysica acta 1989;1003(2):167-74.
1989: Mol M J; Stuyt P M; Stalenhoef A F
[Efficacy and safety of simvastatin, a new cholesterol-lowering drug]
Nederlands tijdschrift voor geneeskunde 1989;133(7):362-6.
1988: Smeets H J; Poddighe J; Stuyt P M; Stalenhoef A F; Ropers H H; Wieringa B
Identification of apolipoprotein E polymorphism by using synthetic oligonucleotides.
Journal of lipid research 1988;29(9):1231-7.
1988: Mol M J; Stuyt P M; Stalenhoef A F; van 't Laar A
Cholesterol synthesis inhibitors in hyperlipidaemia.
Lancet 1988;1(8585):597.
1988: Mol M J; Erkelens D W; Gevers Leuven J A; Schouten J A; Stalenhoef A F
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
Atherosclerosis 1988;69(2-3):131-7.
1988: Demacker P N; Hijmans A G; Stalenhoef A F; van 't Laar A
Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo.
Atherosclerosis 1988;69(2-3):173-83.
1987: Brenninkmeijer B J; Stuyt P M; Demacker P N; Stalenhoef A F; van 't Laar A
Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype.
Journal of lipid research 1987;28(4):361-70.
1986: Mol M J; Erkelens D W; Leuven J A; Schouten J A; Stalenhoef A F
Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.
Lancet 1986;2(8513):936-9.
1985: Stuyt P M; Stalenhoef A F; Demacker P N; Van 't Laar A
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Atherosclerosis 1985;55(1):51-62.
1983: Demacker P N; van Sommeren-Zondag D F; Stalenhoef A F; Stuyt P M; van't Laar A
Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3.
Clinical chemistry 1983;29(4):656-63.
1982: Stuyt P M; Stalenhoef A F; Demacker P N; van't Laar A
Hyperlipoproteinemia type V and apolipoprotein E4.
Lancet 1982;2(8304):934.
1982: Stalenhoef A F; Demacker P N; Lutterman J A; van't Laar A
Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia.
Diabetologia 1982;22(6):489-91.
1982: Demacker P N; Schade R W; Stalenhoef A F; Stuyt P M; van't Laar A
Influence of contraceptive pill and menstrual cycle on serum lipids and high-density lipoprotein cholesterol concentrations.
British medical journal (Clinical research ed.) 1982;284(6324):1213-5.
1982: Stuyt P M; Demacker P N; Stalenhoef A F; Schade R W; Lutterman J A; van't Laar A
Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.
The Netherlands journal of medicine 1982;25(8):245-54.
1981: Stalenhoef A F; Demacker P N; Lutterman J A; Van't Laar A
Severe hypertriglyceridaemia associated with altered apolipoprotein C and E composition of the triglyceride-rich lipoproteins.
The Netherlands journal of medicine 1981;24(4):145-51.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Anton Stalenhoef

Research Profile (preview)

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Anton Stalenhoef (preview)

All Publications